Last reviewed 2026-05-18 · How we verify

ATH3G10

Athera Biotechnologies AB · Phase 2 active Small molecule Quality 10/100

ATH3G10 is a Small molecule drug developed by Athera Biotechnologies AB. It is currently in Phase 2 development. Also known as: PC-mAB.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	ATH3G10
Also known as	PC-mAB
Sponsor	Athera Biotechnologies AB
Modality	Small molecule
Phase	Phase 2

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ATH3G10 CI brief — competitive landscape report
ATH3G10 updates RSS · CI watch RSS
Athera Biotechnologies AB portfolio CI

Frequently asked questions about ATH3G10

What is ATH3G10?

ATH3G10 is a Small molecule drug developed by Athera Biotechnologies AB.

Who makes ATH3G10?

ATH3G10 is developed by Athera Biotechnologies AB (see full Athera Biotechnologies AB pipeline at /company/athera-biotechnologies-ab).

Is ATH3G10 also known as anything else?

ATH3G10 is also known as PC-mAB.

What development phase is ATH3G10 in?

ATH3G10 is in Phase 2.

Manufacturer: Athera Biotechnologies AB — full pipeline
Also known as: PC-mAB

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing